CompletedPHASE1, PHASE2NCT04119674

Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma

Studying Astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zhejiang Cancer Hospital
Principal Investigator
Chen Ming
Zhejiang Cancer Hospital
Intervention
Drug is Anlotinib.(drug)
Enrollment
33 target
Eligibility
18-70 years · All sexes
Timeline
20192022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04119674 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma

← Back to all trials